COMPANY
Clinical Phase 1
Profile checked Oct 10, 2026
Keywords: Allergic Disease
Timeline
- Trial start Phase 1: A Study to Find a Suitable Dose of Exl-111 for Further Research source ↗
- Raise Private equity round — Series A: $70M (total, as published), announced Oct 13, 2025. Source: company's own press page. source ↗
Upcoming milestones
- Dec 7, 2026 (ESTIMATED) · Phase 1 · A Study to Find a Suitable Dose of Exl-111 for Further Research · NCT07356713
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $70.0M. Last 2 years.
- Private equity round — Series A: $70M (total, as published), announced Oct 13, 2025. Source: company's own press page. source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|
| NCT07356713 | A Study to Find a Suitable Dose of Exl-111 for Further Research | Phase 1 | Recruiting | Jan 8, 2026 | Dec 7, 2026 (estimated) |
